Join Growin Stock Community!

Kamada ltd.KMDA.US Overview

US StockHealthcare
(No presentation for KMDA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

KMDA AI Insights

KMDA Overall Performance

KMDA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

KMDA Recent Performance

2.99%

Kamada ltd.

0.05%

Avg of Sector

-0.31%

S&P500

KMDA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

KMDA Key Information

KMDA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

KMDA Profile

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Price of KMDA

KMDA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

KMDA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.35
PE Ratio (TTM)
24.86
Forward PE
25.19
PS Ratio (TTM)
2.87
PB Ratio
1.93
Price-to-FCF
28.53
METRIC
VALUE
vs. INDUSTRY
Gross Margin
43.75%
Net Margin
11.70%
Revenue Growth (YoY)
10.36%
Profit Growth (YoY)
13.55%
3-Year Revenue Growth
13.42%
3-Year Profit Growth
15.37%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.35
PE Ratio (TTM)
24.86
Forward PE
25.19
PS Ratio (TTM)
2.87
PB Ratio
1.93
Price-to-FCF
28.53
Gross Margin
43.75%
Net Margin
11.70%
Revenue Growth (YoY)
10.36%
Profit Growth (YoY)
13.55%
3-Year Revenue Growth
13.42%
3-Year Profit Growth
15.37%

  • When is KMDA's latest earnings report released?

    The most recent financial report for Kamada ltd. (KMDA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating KMDA's short-term business performance and financial health. For the latest updates on KMDA's earnings releases, visit this page regularly.

  • Where does KMDA fall in the P/E River chart?

    According to historical valuation range analysis, Kamada ltd. (KMDA)'s current price-to-earnings (P/E) ratio is 19.75, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of KMDA?

    According to the latest financial report, Kamada ltd. (KMDA) reported an Operating Profit of 7.8M with an Operating Margin of 16.6% this period, representing a growth of 47.07% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is KMDA's revenue growth?

    In the latest financial report, Kamada ltd. (KMDA) announced revenue of 47.01M, with a Year-Over-Year growth rate of 12.63%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does KMDA have?

    As of the end of the reporting period, Kamada ltd. (KMDA) had total debt of 11.47M, with a debt ratio of 0.03. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does KMDA have?

    At the end of the period, Kamada ltd. (KMDA) held Total Cash and Cash Equivalents of 72M, accounting for 0.19 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does KMDA go with three margins increasing?

    In the latest report, Kamada ltd. (KMDA) achieved the “three margins increasing” benchmark, with a gross margin of 42%%, operating margin of 16.6%%, and net margin of 11.3%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess KMDA's profit trajectory and future growth potential.

  • Is KMDA's EPS continuing to grow?

    According to the past four quarterly reports, Kamada ltd. (KMDA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.09. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of KMDA?

    Kamada ltd. (KMDA)'s Free Cash Flow (FCF) for the period is 6.83M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 66.02% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.